Liver toxicity of antiretroviral treatments;Toxicité hépatique des antirétroviraux

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 2, 2003, Pages 155-158

  Pialoux, Gilles ^a   Bonnard, Philippe ^a   Rozenbaum, Willy ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MITOCHONDRION; MORBIDITY; MORTALITY; REVIEW;

ANTI-HIV AGENTS; HEPATITIS, TOXIC; HUMANS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 17644439560     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicicity: a challenge for the hepatologist? J Hepatol 2002;36:283-94.
2. Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002;29:378-87.
3. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containning antiretroviral therapy. AIDS 2001;15:1261-8.
4. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995;90:1433-6.
5. Biour M, Poirier JM. Hépatotoxicité des antirétroviraux in «Médicaments du Sida de l'enfant et de l'adulte» Pons G, Treluyer JM, Blanche S, Rouzioux Ch, Salmon D. Springer Verlag, 2001.
6. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-F32.
7. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999;15:367-73.
8. Bica I, Mc Govern B, Dhar R, Stone D, Mc Gowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with HIV-infection. Clin Infect Dis 2001;32:492-7.
9. Gouezel P, Salmon D, Pialoux G. Co-infection VIH-VHC à l'hôpital, enquête nationale (APPIT/AP-HP). In VS juin 2001; collection Rapports, février 2002.
10. Pol S, Vallet-Pichard A, Fontaine H. Hepatitis C and HIV co-infection at the era of HAART. J of Virol Hepatitis 2002;9:1-8.
11. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B infection. JAMA 2000;283:74-80.
12. Soriano V, Sulkowski MS, Bergin C. Care of patients with HIV and HIV co-infection: recommendations from the HIV-HCV international panel. AIDS 2002;16:1-16.
13. «Prise en charge des personnes infectées par le VIH». Recommandations du groupe d'experts. Rapports 2002 sous la direction du Pr JF Delfraissy. Médecine-sciences/Flammarion.
14. Palella FJ, Delaney KM, Moorman AC, Loreless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immodeficiency virus infection. HIV out patients Study Investigators. N Engl J Med 1998;338:853-60.
15. Sutinen J, Häkkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, et al. Increased fat accumulation in the liver in HIV infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002;2183-93.
16. Behrens GMN, Dejam A, Schmidt H. Impaired glucose tolerance, β cell fonction and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-F70.
17. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Coopoer DA. A Syndrom of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998,12:F51-58.
18. Garg A, Misra A. Hepatic steatosis, insulin resistance and adipose tissue discorders. J Clin Endocrinol Metab 2002;87:3019-22.
19. Lui A, Karter D, Turrett C. Another case of breast hypertrophy in a patient treated with indinavir. Clin Infect Dis 1998;26:1482.
20. Sha BE, Proia LA, Kessler HA. Adverse affects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA 2000;284:2723.
21. Sulkowski MS, Thomas DL, Mehta SH, Chaison SH, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-9.
22. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000;133:447-54.
23. Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998;27:1255-8.
24. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998;12:116-7.
25. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol Chem 2001;276:37514-9.